What drugs are Aminosalicylates?

Sulfasalazine (brand name: Azulfidine) and the 5-aminosalicylate drugs (sample brand names: Delzicol, Asacol HD, Pentasa, Salofalk, Dipentum, Colazal, Apriso, Lialda) are used to treat inflammatory bowel disease.

Is mesalamine the same as Mezavant?

Mezavant 1.2g is a higher-strength, delayed and extended-release tablet formulation of mesalamine, a drug also known as 5-aminosalicylic acid (5-ASA). active, mild to moderate ulcerative colitis (UC), and when effective can lead to a remission the disease.

Is Mezavant the same as mesalazine?

The Mezavant tablet contains a core of mesalazine (5-aminosalicylic acid) 1.2g formulated in a multi-matrix system.

Can I buy aminosalicylates?

Can I buy aminosalicylates or are they just on prescription? These medicines are prescription-only and are usually prescribed by a specialist doctor.

What class of drug is Mezavant?

What MEZAVANT is used for. The name of your medicine is MEZAVANT 1.2 g, gastro-resistant, prolonged release tablets. It contains the active ingredient mesalazine (also called 5-aminosalicylic acid or 5-ASA), an anti-inflammatory drug for the treatment of ulcerative colitis.

What is mezavant used to treat?

MEZAVANT contains the active ingredient mesalazine. MEZAVANT is used for the treatment of ulcerative colitis. For more information, see Section 1. Why am I using MEZAVANT? in the full CMI. What should I know before I use MEZAVANT?

How many mg of mesalazine are in mezavant XL?

Mezavant XL 1200 mg, gastro-resistant, prolonged release tablets. 2. Qualitative and quantitative composition Each tablet contains 1200mg mesalazine.

Is mezavant gluten free?

MEZAVANT tablets do not contain gluten, lactose or phthalates. What dosage forms it comes in: MEZAVANT 1.2g delayed- and extended-release tablets are available as red-brown, oval-shaped, film-coated tablets marked on one side with “S476”.

What are the adverse drug reactions (ADRs) associated with mezavant?

The most frequently reported adverse drug reactions (ADRs) within the pooled safety analysis of clinical studies with Mezavant, including 3,611 patients, were colitis (including ulcerative colitis) 5.8%, abdominal pain 4.9%, headache 4.5%, liver function test abnormal, 2.1%, diarrhoea 2.0%, and nausea 1.9%.